Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment

Friday, July 21, 2017

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha–1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha–1 Antitrypsin Deficiency (AATD). The proposed...

Click For Search Options

Foundation president and CEO urges Alphas to find their place in the Alpha-1 Community

Thursday, June 29, 2017

CHICAGO, Illinois – Henry Moehring, president and CEO of the Alpha–1 Foundation, presided over the 26th and largest National Education Conference of the Alpha–1 community since its inception, he said in his Foundation update...

Alpha-1 Foundation Accepting Proposals for the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Wednesday, June 28, 2017

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. This award is named after John W. Walsh, who dedicated his life’s work to finding...

Barbara Pusey honored in memoriam at Alpha–1 awards and recognition night

Monday, June 26, 2017

Barbara Pusey, who was the first AlphaNet Coordinator for the augmentation therapy marketed in the United States as Zemaira and was a major influence in building the AlphaNet Zemaira program into what it is today, was recognized posthumously, with...

Grifols announces $1 million grant to support Alpha-1 Foundation’s John W. Walsh Research Fund

Monday, June 26, 2017

Washington, DC — Grifols announced that it will award a million-dollar grant to support the John. W. Walsh Research Fund, the Foundation’s peer-reviewed research program named in honor of Walsh, the Foundation’s co-founder...

More Than 600 to Hear Top World Experts on Alpha-1 at National Conference in Chicago

Monday, June 5, 2017

CHICAGO, June 5, 2017 – More than 600 people with Alpha–1 Antitrypsin Deficiency – the most common known genetic cause of chronic obstructive pulmonary disease (COPD) – along with their family members, caregivers and...

Alpha-1 Foundation lauds COPD National Action Plan

Monday, May 22, 2017

The Alpha–1 Foundation applauded today’s launch of the COPD National Action Plan, calling it “a strong tool to identify people affected by genetic COPD caused by Alpha–1, leading to proper diagnoses and treatment for their...

Alphas in Ireland set to lose access to augmentation therapy

Friday, February 17, 2017

More than 20 people in Ireland who have severe Alpha-1 lung disease are facing the loss of “life-changing” augmentation therapy within weeks following its rejection by the Health Service Executive (HSE). Noel G....

Alabama medical practice becomes Alpha-1 Clinical Resource Center

Friday, February 10, 2017

Chest Medicine (CMED) of Cullman, Alabama has been designated as an Alpha-1 Foundation Clinical Resource Center program —one of just two in the state. G. Scott Warner, MD, middle, with nurse practitioners Kristy Keiffer and Glenda...

Patients increasingly influence direction of medical research

Wednesday, December 7, 2016

Patients and their advocates are getting an ever-larger voice in how medical research is carried out. They participate in the design of experiments and have a greater say in what outcomes they care about most — and it's not always simply...

Scientists battle in court over lucrative patents for gene-editing technology

Tuesday, December 6, 2016

The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday. Emmanuelle Charpentier (left) and Jennifer Doudna A gene-editing technology called CRISPR-cas9 could be...

Ryan says Obamacare repeal is top priority, says people won’t lose healthcare coverage

Monday, December 5, 2016

House Speaker Paul D. Ryan says the next Congress will pursue a repeal of Obamacare immediately, even before Republicans have a replacement in hand, though that repeal will not pull the rug out from 20 million-plus Americans who gained coverage...

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

Friday, December 2, 2016

The medical journal The Lancet Respiratory Medicine on Thursday, Dec. 1, published findings of the RAPID Open Label Extension study of augmentation therapy for patients with emphysema and Alpha-1 Antitrypsin Deficiency. N. Gerard...

1 2 3 4 5 6 7 8 9 10 Next Last

Top Stories